Bicycle Therapeutics logo

BCYC - Bicycle Therapeutics News Story

$15.37 -0.2  -1.5%

Last Trade - 21/02/20

Sector
Healthcare
Size
Small Cap
Market Cap £212.1m
Enterprise Value £138.1m
Revenue £7.38m
Position in Universe 3507th / 6408

BRIEF-Bicycle Therapeutics PLC - Expects To Initiate A Phase IIA Clinical Trial Of Its BT1718 Product Candidate

Wed 20th November, 2019 2:54pm
Nov 20 (Reuters) - Bicycle Therapeutics PLC  BCYC.O :
    * BICYCLE THERAPEUTICS PLC - EXPECTS TO INITIATE A PHASE IIA
CLINICAL TRIAL OF ITS BT1718 PRODUCT CANDIDATE IN 2020
    * BICYCLE THERAPEUTICS PLC - EXPECTS TO PROVIDE INTERIM DATA
REGARDING ITS PHASE I CLINICAL TRIAL OF BT5528 IN 2020
    * BICYCLE THERAPEUTICS -  EXPECTS TO PROVIDE INTERIM DATA
REGARDING PHASE I CLINICAL TRIAL OF BT5528, INITIAL A PHASE I
CLINICAL TRIAL OF BT8009 IN 2020
    * BICYCLE THERAPEUTICS PLC - EXPECTS TO ADVANCE
INVESTIGATIONAL
NEW DRUG APPLICATION ENABLING ACTIVITIES REGARDING BT7480 IN
2020

Source (https://bit.ly/2O29wTv)
Further company coverage:  BCYC.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.